The ROS1ders Issues RFA for $75K ROS1+ Cancer Research Grant
The Californer/10231160

SACRAMENTO, Calif. - Californer -- The ROS1ders is pleased to issue their inaugural Request for Application (RFA) to study ROS1-positive (ROS1+) cancer.

"ROS1+ cancer is relatively rare, occurring in just 1-2% of non-small cell lung cancer and other types of cancer," said Janet Freeman-Daily, MS, co-founder and president of The ROS1ders. "While oral targeted therapies are approved to treat it, the drugs don't work for everyone, and they eventually stop working. We need more research to improve quality of life and survival for all patients with this disease."

The ROS1+ Cancer Innovation Award aims to fund high-risk, high-reward research projects focused on ROS1+ cancer. The one-year $75,000 seed grant can be used for pre-clinical, translational, or clinical research and is open to investigators who hold a doctorate degree and a faculty appointment at an academic or non-profit research institution anywhere in the world.

More on The Californer

• The 2nd Aollywood Five Continents Film Festival Nominations Were Announced: "All Quiet on the Western Front" Led With 7 Nominations
• Human Matriptase/ST14 Protein (High Purity)
• Myristoyl-Coenzyme A (Highly Pure)
• Dr. Kelli Ward and Martha Boneta Fain join the advisory board of Legacy PAC , a partner of Veterans for Trump
• My Refuge House Hosts Much Ado for Freedom

"Seed grants, as the name suggests, allow for the generation of initial data to support larger research endeavors," said D. Ross Camidge, MD, PhD, Professor of Medicine/Oncology at the University of Colorado and a member of The ROS1ders Scientific Advisory Board. "While some seeds fail, others grow into mighty trees - they can be the real seeds of breakthroughs."

The award program uses a two-step application process. An applicant must first submit a letter of intent (LOI) due March 31, 2023. A subset of those applicants will be invited to submit a full application due June 15, 2023. Award recipients will be announced in late summer. For more information, visit https://theros1ders.org/seed-grant-program.

More on The Californer

• 2023 Employee Handbook Templates Now Available
• Passive Income for Retirees - Income Ideas for Retirees
• Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Stanley Black & Decker, Inc. (SWK)
• Mercy Street to Host the Largest Opening Day Event in the Organization's 20 Year History
• The Nashville International Chopin Piano Competition Announces the Alexei Sultanov Memorial Discovery Prize

About the ROS1ders

The ROS1ders, Inc. is a non-profit public benefit corporation that brings together a global group of patients and their family members living with ROS1+ cancer. It seeks to improve outcomes for all ROS1+ cancers through community, education, and research. Founded in 2015 by ROS1+ lung cancer patients, it is the largest collection of ROS1+ patients and caregivers in the world, with hundreds of members from dozens of countries. The organization is internationally recognized in the oncology and patient advocacy communities as experts in their disease. Please visit theros1ders.org to learn more.